Protein C deficiency is an inherited condition that impairs your body’s ability to regulate blood clotting, raising your risk of developing dangerous clots in veins. Mild forms affect an estimated 1 in 200 to 1 in 500 people, though many never know they have it until a clot occurs. Clinically significant deficiency is rarer, affecting roughly 1 in 20,000 people.
How Protein C Keeps Clotting in Check
Your blood has a built-in braking system to prevent clots from growing out of control. Protein C is one of the key brakes. When activated, it cuts apart two helper molecules (called cofactors) that the clotting system depends on to build clots. Without enough functioning protein C, those cofactors stay active longer than they should, and clots can form in places where they’re not needed, particularly in the deep veins of the legs and lungs.
Protein C is made in the liver and requires vitamin K to function. This detail becomes important when it comes to treatment, because certain blood thinners that block vitamin K can actually make the condition temporarily worse before it gets better.
Type I vs. Type II Deficiency
There are two forms, and the distinction matters for diagnosis. In Type I deficiency, your body simply doesn’t produce enough protein C. Blood tests show both the amount of protein C and its activity are low in proportion to each other. This is the more common form.
In Type II deficiency, your body makes a normal amount of protein C, but the protein itself is defective. Lab tests show normal protein C levels but reduced activity. Because standard screening sometimes only measures the amount of protein and not how well it works, Type II can be missed if the right tests aren’t ordered. Identifying which type you have helps clarify the genetic pattern in your family and guides testing for relatives.
Symptoms and Clotting Risks
Most people with mild protein C deficiency have no symptoms for years or even decades. The condition typically announces itself through a venous thromboembolism (VTE), which means a blood clot in a deep vein, usually in the leg, or a clot that travels to the lungs (pulmonary embolism). These events often happen during periods of additional clotting risk: after surgery, during long periods of immobility, during pregnancy, or while taking estrogen-containing birth control.
Some people experience recurrent clots, while others have a single event and then none again. The severity depends heavily on whether you inherited the deficiency from one parent (heterozygous) or both (homozygous). Inheriting it from both parents is extremely rare, affecting roughly 1 in 4 million infants, and produces a dramatically more severe condition.
Purpura Fulminans in Newborns
Infants born with virtually no functioning protein C can develop purpura fulminans, a life-threatening condition that causes widespread clotting in tiny blood vessels, leading to hemorrhagic skin necrosis and organ damage. The clinical picture is one of disseminated intravascular coagulation, where the body both clots and bleeds at the same time. This condition is often fatal without early recognition and immediate replacement of protein C through plasma infusions or protein C concentrate. Affected infants require ongoing anticoagulation therapy to survive.
The Warfarin Paradox
One of the most counterintuitive dangers of protein C deficiency involves warfarin, a common blood thinner. Warfarin works by blocking vitamin K, which shuts down several clotting factors. But it also shuts down protein C and a related protein called protein S.
Here’s the problem: protein C has a shorter lifespan in the blood than the clotting factors warfarin is meant to suppress. So in the first few days of warfarin therapy, protein C drops before the clotting factors do, creating a temporary window where the blood actually becomes more prone to clotting, not less. In someone who already has low protein C, this imbalance can trigger clots in small skin vessels, causing warfarin-induced skin necrosis. These reactions typically appear 3 to 5 days after starting treatment, especially when warfarin is started at a high dose or without a bridging blood thinner like heparin.
This is why people with known protein C deficiency who need warfarin are started on heparin first, with warfarin introduced gradually while the heparin provides immediate protection.
How It’s Diagnosed
Diagnosis involves blood tests that measure both the amount of protein C in your blood and how well it functions. Getting accurate results requires careful timing. Several common situations can temporarily lower protein C levels and produce misleading results:
- Active blood clots consume protein C, so testing during or immediately after a clotting event may show falsely low levels.
- Warfarin and other vitamin K blockers reduce protein C production, making it impossible to interpret results while you’re on these medications.
- Liver disease impairs protein C production since the liver is where it’s made.
- Certain newer blood thinners (direct oral anticoagulants) can artificially raise protein C levels in one type of test while leaving another type unaffected, creating confusing results.
For these reasons, testing is ideally done when you’re off anticoagulants (when safe), well past any acute clotting event, and without active liver problems. Results are often confirmed with repeat testing and family screening to distinguish a true inherited deficiency from a temporary dip.
Pregnancy and Hormonal Risks
Pregnancy is a particularly high-risk period for women with protein C deficiency. In one study, thromboembolism occurred during 33% of pregnancies in protein C-deficient women, compared to 5% in controls. Among those who did not receive preventive blood thinners, the rate climbed to 45%. Pregnancy loss was also somewhat higher (33% vs. 19%), though that difference did not reach statistical significance.
Women with protein C deficiency who have a personal or family history of clots are generally treated with preventive heparin injections throughout pregnancy. Estrogen-containing oral contraceptives are not recommended, as they independently increase clotting risk and compound the danger.
Long-Term Management
For people with mild deficiency who have never had a clot, no treatment may be needed. The focus shifts to avoiding situations that stack additional clotting risks: prolonged immobility after surgery, unnecessary estrogen use, and dehydration during long flights or illness. Knowing your status lets you and your care team take precautions during these high-risk windows.
After a first clot, most people are placed on long-term anticoagulation. The duration depends on the circumstances of the clot, whether it was provoked by something like surgery or occurred spontaneously, and whether you’ve had recurrent events. Some people remain on blood thinners indefinitely. The choice of anticoagulant takes the warfarin risk into account, and newer direct oral anticoagulants are increasingly used as alternatives, though the decision is individualized.
Family screening is often recommended once a case is identified, since first-degree relatives have a 50% chance of carrying the same genetic variant. Identifying affected family members before they experience a clot allows for preventive measures during high-risk situations rather than waiting for a potentially dangerous first event.